Physician profile
Mark R Windt
NPI 1689625600
$969.54
in general payments reported to CMS, 2019-2025
17 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $38.94 · 2021: $28.07 · 2022: $174 · 2023: $284 · 2024: $159 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $589.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $178.43 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $134.79 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $116.29 | 2019-2025 | Tezspire, Breztri, Fasenra |
| United Therapeutics Corporation | $79.88 | 2023-2025 | Tyvaso, Tyvaso |
| Abbvie INC. | $78.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.51 | 2022-2024 | Cuvitru |
| 3b Medical, INC. | $50.64 | 2023-2024 | Luna |
| Blueprint Medicines Corporation | $46.63 | 2024 | Ayvakit |
| Mylan Specialty L.P. | $43.30 | 2023 | Yupelri |
| Aimmune Therapeutics, INC. | $41.33 | 2020-2021 | |
| Insmed, INC. | $30.42 | 2025 | Arikayce |
| Novartis Pharmaceuticals Corporation | $29.38 | 2021-2023 | |
| Medline Industries LP | $22.90 | 2024 | |
| Genzyme Corporation | $20.06 | 2022 | |
| Csl Behring | $16.82 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $13.35 | 2019 | |
| Pfizer INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Windt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.